Search

Your search keyword '"Yang, Xue"' showing total 25 results
Start Over Author "Yang, Xue" Search Limiters Peer Reviewed Journal thoracic cancer
25 results on '"Yang, Xue"'

2. Investigation on the incidence and risk factors of lung cancer among Chinese hospital employees

Author

Chen, Zi‐Hao, primary, Chen, Zhi‐Yong, additional, Kang, Jing, additional, Chu, Xiang‐Peng, additional, Fu, Rui, additional, Zhang, Jia‐Tao, additional, Qi, Yi‐Fan, additional, Chen, Jing‐Hua, additional, Lin, Jun‐Tao, additional, Jiang, Ben‐Yuan, additional, Yang, Xue‐Ning, additional, Wu, Yi‐Long, additional, Zhong, Wen‐Zhao, additional, and Nie, Qiang, additional

Published
2022
Full Text
View/download PDF

3. Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non‐small cell lung cancers

Author

Zhang, Jia−Tao, primary, Dong, Song, additional, Ji, Li−Yan, additional, Zhou, Jia−Ying, additional, Chen, Zhi− Hong, additional, Su, Jian, additional, Zhu, Qing−Ge, additional, Wang, Meng−Min, additional, Ke, E−E., additional, Sun, Hao, additional, Li, Xue−Tao, additional, Yang, Jin−Ji, additional, Zhou, Qing, additional, Zhang, Xu− Chao, additional, Gao, Xuan, additional, Yang, Xue−Ning, additional, Xia, Xuefeng, additional, Yi, Xin, additional, Zhong, Wen−Zhao, additional, and Wu, Yi−Long, additional

Published
2022
Full Text
View/download PDF

5. High SHP2 expression determines the efficacy of PD ‐1/ PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer

Author

Feng, Hui‐Bo, primary, Chen, Yu, additional, Xie, Zhi, additional, Jiang, Jie, additional, Zhong, Yu‐Min, additional, Guo, Wei‐Bang, additional, Yan, Wen‐Qing, additional, Lv, Zhi‐Yi, additional, Lu, Dan‐Xia, additional, Liang, Hong‐Ling, additional, Xu, Fang‐Ping, additional, Yang, Jin‐Ji, additional, Yang, Xue‐Ning, additional, Zhou, Qing, additional, Zhang, Dong‐Kun, additional, Zhang, Zhou, additional, Chuai, Shao‐Kun, additional, Zhang, Heng‐Hui, additional, Wu, Yi‐Long, additional, and Zhang, Xu‐Chao, additional

Published
2021
Full Text
View/download PDF

6. Precise resection of multiple pulmonary nodules using a three‐dimensional reconstruction model: A case report

Author

Chu, Xiang‐Peng, primary, Chen, Zi‐Hao, additional, Lin, Shao‐Min, additional, Tang, Wen‐Fang, additional, Zhang, Jia‐Tao, additional, Lai, Yao‐Ming, additional, Fu, Rui, additional, Qiu, Zhen‐Bin, additional, Lin, Jun‐Tao, additional, Nie, Qiang, additional, Yang, Xue‐Ning, additional, Wu, Yi‐Long, additional, and Zhong, Wen‐Zhao, additional

Published
2021
Full Text
View/download PDF

8. Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer

Author

Lv, Chunxin, Liu, Xiuju, Zheng, Qiwen, Chen, Hanxiao, Yang, Xue, Zhong, Jia, Wang, Yuyan, Duan, Jianchun, Wang, Zhijie, Bai, Hua, Wu, Meina, Zhao, Jun, Wang, Jie, Wang, Ziping, An, Tongtong, and Zhuo, Minglei

Subjects
Male, Lung Neoplasms, Gene Expression, Original Articles, Kaplan-Meier Estimate, Second‐line chemotherapy, Middle Aged, Immunohistochemistry, Magnetic Resonance Imaging, Small Cell Lung Carcinoma, topotecan, DNA Topoisomerases, Type I, Recurrence, Biomarkers, Tumor, Humans, Original Article, Female, small cell lung cancer, topoisomerase‐1, Topoisomerase I Inhibitors, Tomography, X-Ray Computed, Aged, Neoplasm Staging
Abstract

Background We evaluated topoisomerase I (TOPO1) expression in patients with small cell lung cancer (SCLC) and identified predictive factors for the efficacy of second‐line topotecan chemotherapy. Methods We retrospectively evaluated the records of SCLC patients treated in our department from January 2007 to December 2016 who received second‐line topotecan chemotherapy. Patients with archived tumor samples were enrolled. TOPO1 expression levels were evaluated by immunohistochemistry, and the relationships between TOPO1 expression, clinical factors, chemotherapy efficacy, and survival were analyzed. Results Of the 78 patients enrolled, 67 showed TOPO1 expression (85.9%). Patients were divided into strong (n = 43) or weak (n = 35) expression groups based on staining intensity. Disease control rates for topotecan were 39.5% and 14.3% in the strong and weak groups, respectively (P = 0.014). Second‐line median progression‐free survival was 2.2 and 2.0 months (P = 0.057), and median overall survival was 8.1 and 6.0 months (P = 0.199) in the strong and weak positive groups, respectively. Patients were also divided into sensitive (n = 47) and refractory (n = 31) disease groups according to the duration from the onset of first‐line therapy to relapse. Median second‐line progression‐free survival was 2.2 and 1.8 months in the sensitive and refractory relapse groups, respectively (P = 0.005). Conclusions TOPO1 expression was prevalent in SCLC patients. Strong expression was associated with an elevated disease control rate after second‐line topotecan chemotherapy. Patients with sensitive disease that relapsed after first‐line chemotherapy had better survival than refractory patients who received second‐line topotecan chemotherapy.

Published
2018

9. Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer

Author

Kang, Jin, Chen, Hua‐Jun, Zhang, Xu‐Chao, Su, Jian, Zhou, Qing, Tu, Hai‐Yan, Wang, Zhen, Wang, Bin‐Chao, Zhong, Wen‐Zhao, Yang, Xue‐Ning, Chen, Zhi‐Hong, Ding, Yan, Wu, Xue, Wang, Mei, Fu, Jian‐Gang, Yang, Zhenfan, Zhang, Xian, Shao, Yang W., Wu, Yi‐Long, and Yang, Jin‐Ji

Subjects
Lung Neoplasms, DNA mismatch repair, Gene Expression Profiling, DNA Mutational Analysis, next‐generation sequencing, Original Articles, NSCLC, Prognosis, resistance, ALK, Crizotinib, hemic and lymphatic diseases, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Bacterial, Mutation, Biomarkers, Tumor, Humans, Original Article, Anaplastic Lymphoma Kinase, Neoplasm Metastasis, Protein Kinase Inhibitors, Neoplasm Staging
Abstract

Background ALK‐tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK‐positive non‐small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better prognosis. Methods Targeted next‐generation sequencing (NGS) mutation profiling was performed on samples from 42 NSCLC patients confirmed positive for ALK rearrangements by fluorescence in situ hybridization or immunohistochemistry who experienced disease progression after crizotinib treatment. Results ALK rearrangements were not confirmed in six patients (14%) with other potential oncogenic drivers identified by NGS, who therefore did not respond to crizotinib and had significantly shorter overall survival (OS) compared to NGS ALK ‐positive patients. Fifteen ALK activating mutations were detected in 8 out of 26 post‐treatment samples (31%), among which ALK L1196M and G1269A were the most common acquired mutations detected in half of the patients with ALK activating mutations. Dynamic monitoring of the genetic evolution in one patient revealed both spatial and temporal heterogeneity of resistant mechanisms during different ALK‐TKI treatment courses. Activation of ALK downstream or bypass pathways was detected in patients without ALK activating mutations, such as genetic alterations in PIK3CA, MET, and KRAS. Interestingly, we identified two patients with acquired mutations in the DNA mismatch repair gene POLE, which resulted in a dramatically increased tumor mutation burden, and might contribute to the poor response to crizotinib. Conclusions Heterogeneous resistant mechanisms have been identified and correlate to diverse responses to crizotinib. Comprehensive and dynamic mutation profiling is required to better predict clinical outcomes.

Published
2018

10. Three‐ dimensional printed navigational template for localizing small pulmonary nodules: A case‐ controlled study

Author

Fu, Rui, primary, Chai, Yun‐Fei, additional, Zhang, Jia‐Tao, additional, Zhang, Tao, additional, Chen, Xiao‐Kun, additional, Dong, Song, additional, Yan, Hong‐Hong, additional, Yang, Xue‐Ning, additional, Huang, Mei‐Ping, additional, Wu, Yi‐Long, additional, Zhuang, Jian, additional, and Zhong, Wen‐Zhao, additional

Published
2020
Full Text
View/download PDF

11. Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma

Author

Wang, Shuhang, primary, Liang, Qiuping, additional, Chi, Yujia, additional, Zhuo, Minglei, additional, An, Tongtong, additional, Duan, Jianchun, additional, Wang, Zhijie, additional, Wang, Yuyan, additional, Zhong, Jia, additional, Yang, Xue, additional, Chen, Hanxiao, additional, Wang, Jie, additional, and Zhao, Jun, additional

Published
2020
Full Text
View/download PDF

12. Low frequency of mutation of epidermal growth factor receptor ( EGFR ) and arrangement of anaplastic lymphoma kinase ( ALK ) in primary pulmonary lymphoepithelioma‐like carcinoma

Author

Yin, Kai, primary, Feng, Hui‐Bo, additional, Li, Lin‐Lin, additional, Chen, Yu, additional, Xie, Zhi, additional, Lv, Zhi‐Yi, additional, Guo, Wei‐Bang, additional, Lu, Dan‐Xia, additional, Yang, Xue‐Ning, additional, Yan, Wen‐Qing, additional, Wu, Yi‐Long, additional, and Zhang, Xu‐Chao, additional

Published
2019
Full Text
View/download PDF

13. Optimal first‐line treatment for advanced thymic carcinoma

Author

Yang, Xue, primary, Zhuo, Minglei, additional, Shi, Anhui, additional, Yang, Shengnan, additional, Wang, Ziping, additional, Wu, Meina, additional, An, Tongtong, additional, Wang, Yuyan, additional, Li, Jianjie, additional, Zhong, Jia, additional, Chen, Hanxiao, additional, Jia, Bo, additional, Dong, Zhi, additional, and Zhao, Jun, additional

Published
2019
Full Text
View/download PDF

14. ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane‐based chemotherapy

Author

Zhong, Jia, primary, Guo, Zihan, additional, Fan, Liping, additional, Zhao, Xinghui, additional, Zhao, Bingqing, additional, Cao, Zhigang, additional, Cheng, Linlin, additional, Shi, Yuanyuan, additional, Li, Xiaoting, additional, Zhang, Yanhua, additional, An, Tongtong, additional, Wu, Meina, additional, Wang, Yuyan, additional, Zhuo, Minglei, additional, Li, Jianjie, additional, Yang, Xue, additional, Chen, Hanxiao, additional, Jia, Bo, additional, and Zhao, Jun, additional

Published
2019
Full Text
View/download PDF

15. High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer.

Author

Feng, Hui‐Bo, Chen, Yu, Xie, Zhi, Jiang, Jie, Zhong, Yu‐Min, Guo, Wei‐Bang, Yan, Wen‐Qing, Lv, Zhi‐Yi, Lu, Dan‐Xia, Liang, Hong‐Ling, Xu, Fang‐Ping, Yang, Jin‐Ji, Yang, Xue‐Ning, Zhou, Qing, Zhang, Dong‐Kun, Zhang, Zhou, Chuai, Shao‐Kun, Zhang, Heng‐Hui, Wu, Yi‐Long, and Zhang, Xu‐Chao

Subjects
LUNG cancer prognosis, LUNG cancer, PROGRAMMED cell death 1 receptors, DRUG efficacy, GENETIC mutation, SEQUENCE analysis, IMMUNOHISTOCHEMISTRY, ANTINEOPLASTIC agents, RETROSPECTIVE studies, CANCER patients, CYTOCHEMISTRY, DESCRIPTIVE statistics, FLUORESCENT antibody technique, SURVIVAL analysis (Biometry), MEMBRANE proteins, ESTERASES, CELL lines, TUMOR markers, IMMUNOTHERAPY, PHARMACODYNAMICS
Abstract

Background: Src homology region 2 domain‐containing phosphatase 2 (SHP2) is a novel target for Kirsten rat sarcoma oncogene (KRAS) mutant cancer. We retrospectively studied the significance of SHP2 in KRAS mutant non‐small cell lung cancer (NSCLC) treated with immunotherapy and its relationship with tumor microenvironment (TME). Methods: Sixty‐one advanced KRAS mutant NSCLC patients who underwent immunotherapy were enrolled. Next‐generation sequencing (NGS) was used to profile mutation status. The expression of SHP2, phospho‐SHP2 (pSHP2), and programmed death ligand 1 (PD‐L1) were analyzed by immunohistochemistry (IHC). Quantitative multiplexed immunofluorescence cytochemistry (mIFC) analysis was conducted to describe the TME. Results: SHP2 was heterogeneously expressed in 32 samples in both tumor cells and immune cells and highly expressed (H‐score >10) in 25 (78.1%) samples. The expression levels of SHP2 and pSHP2 were positively correlated. Stromal SHP2 (s‐SHP2) was higher in tumors with PD‐L1 ≥50% versus PD‐L1 <50% (p = 0.039). By quantitative mIFC analysis, the expression of s‐SHP2 had positive correlation with CD8, CD4, CD68, and PD‐L1 levels in stromal area. Patients with high SHP2 expression made up 100.0% of the partial respond (PR) and 80.0% of the stable disease (SD), whereas 50.0% of the progress disease (PD). High SHP2 expression was associated with longer progression‐free survival (PFS) and overall survival (OS) (p < 0.001, p = 0.013). Patients with high expression of both SHP2 and PD‐L1 had longer PFS (p < 0.001). Conclusion: High SHP2 expression could predict the efficacy of immunotherapy and better survival in advanced KRAS mutant NSCLC. SHP2 may function in both tumor cells and immune cells, warranting further study on the potential diverse effects of SHP2 inhibition in TME. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

16. Simultaneous tongue metastasis from malignant pleural mesothelioma: Case report and literature review.

Author

Huang, Chuan and Yang, Xue

Subjects
*COMPUTED tomography, *IMMUNOHISTOCHEMISTRY, *MESOTHELIOMA, *METASTASIS, *PLEURAL effusions, *PLEURAL tumors, *SYMPTOMS, TONGUE tumors
Abstract

Malignant pleural mesothelioma (MPM) is a rare neoplasm of the serosal membranes. MPM usually manifests as local invasion, rarely with distant haematogenous metastases in different organs. Few cases of tongue metastasis have been documented. Here, we report the case of a 68‐year‐old man diagnosed with malignant pleural epithelioid mesothelioma together with a simultaneous tongue lesion, which was found to be metastatic malignant mesothelioma. Tongue metastasis from MPM is rare and the oral symptoms it causes could be an early sign of clinical manifestation. For patients with oral symptoms and a newly discovered tongue lesion, clinicians should be aware of the possibility of tongue metastasis and search for a primary malignancy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

17. Nomogram to predict cause‐specific mortality in extensive‐stage small cell lung cancer: A competing risk analysis

Author

Zhong, Jia, primary, Zheng, Qiwen, additional, An, Tongtong, additional, Zhao, Jun, additional, Wu, Meina, additional, Wang, Yuyan, additional, Zhuo, Minglei, additional, Li, Jianjie, additional, Zhao, Xinghui, additional, Yang, Xue, additional, Jia, Bo, additional, Chen, Hanxiao, additional, Dong, Zhi, additional, Wang, Jingjing, additional, Chi, Yujia, additional, Zhai, Xiaoyu, additional, and Wang, Ziping, additional

Published
2019
Full Text
View/download PDF

18. Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database

Author

Zhuo, Minglei, primary, Zheng, Qiwen, additional, Chi, Yujia, additional, Jia, Bo, additional, Zhao, Jun, additional, WU, Meina, additional, AN, Tongtong, additional, Wang, Yuyan, additional, LI, Jianjie, additional, Zhao, Xinghui, additional, Yang, Xue, additional, Zhong, Jia, additional, Chen, Hanxiao, additional, Dong, Zhi, additional, Wang, Jingjing, additional, Zhai, Xiaoyu, additional, and Wang, Ziping, additional

Published
2019
Full Text
View/download PDF

20. Survival comparison of right and left side non‐small cell lung cancer in stage I–IIIA patients: A Surveillance Epidemiology and End Results (SEER) analysis

Author

Jia, Bo, primary, Zheng, Qiwen, additional, Qi, Xinmeng, additional, Zhao, Jun, additional, Wu, Meina, additional, An, Tongtong, additional, Wang, Yuyan, additional, Zhuo, Minglei, additional, Li, Jianjie, additional, Zhao, Xinghui, additional, Yang, Xue, additional, Zhong, Jia, additional, Chen, Hanxiao, additional, Dong, Zhi, additional, Shi, Youwu, additional, Du, Feng, additional, Wang, Jingjing, additional, Chi, Yujia, additional, Zhai, Xiaoyu, additional, and Wang, Ziping, additional

Published
2019
Full Text
View/download PDF

21. Prophylactic air-extraction strategy after thoracoscopic wedge resection

Author

Zhang, Jia-Tao, primary, Tang, Yi-Chun, additional, Lin, Jun-Tao, additional, Dong, Song, additional, Nie, Qiang, additional, Jiang, Ben-Yuan, additional, Yan, Hong-Hong, additional, Wen, Zheng-Wei, additional, Wu, Yue, additional, Yang, Xue-Ning, additional, Wu, Yi-Long, additional, and Zhong, Wen-Zhao, additional

Published
2018
Full Text
View/download PDF

22. Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma.

Author

Yin, Kai, Feng, Hui‐Bo, Li, Lin‐Lin, Chen, Yu, Xie, Zhi, Lv, Zhi‐Yi, Guo, Wei‐Bang, Lu, Dan‐Xia, Yang, Xue‐Ning, Yan, Wen‐Qing, Wu, Yi‐Long, and Zhang, Xu‐Chao

Subjects
EPIDERMAL growth factor, LUNG tumors, MEDICAL records, GENETIC mutation, RETROSPECTIVE studies, DISEASE progression, ANAPLASTIC lymphoma kinase, ACQUISITION of data methodology
Abstract

Background: Primary pulmonary lymphoepithelioma‐like carcinoma (PLELC) is a rare and unique subtype of lung cancer. However, the prevalence of driver alterations, such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, and the response of tyrosine kinase inhibitor (TKIs) in PLELC has not been thoroughly investigated. Method: We retrospectively reviewed the genetic profiles and treatment course of 330 PLELC patients at the Guangdong Lung Cancer Institute (GLCI) from 1st January, 2008 to 30th December, 2018. We searched and analyzed related literature published in PubMed and Web of Science from 1st January, 2000 and 31th August, 2019 based on their mention of "driver mutations" and "the response of TKIs to mutant PLELC". Results: Genetic alterations of EGFR/ALK were tested in 203 patients (203/330, 61.5%). Five patients (5/175, 2.9%) had EGFR mutation and three patients (3/140, 2.1%) had ALK alteration. From the total of 15 articles identified from electronic searches, 1071 PLELC cases mentioned the driver mutations. EGFR mutation and ALK rearrangement were detected in 15 patients and one patient, respectively. In total, there were four EGFR/ALK mutant PLELC patients who received targeted therapy as palliative treatment at the GLCI and in the literature. However, there was disease progression in all cases one month after use of TKIs. Conclusion: The mutation rates of EGFR and ALK were low in PLELC. EGFR and ALK TKIs showed limited response in EGFR/ALK mutant PLELC. Further studies are needed to explore other molecular targets to optimize the therapeutic strategy for PLELC. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

23. Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma

Author

Zhong, Jia, primary, Zheng, Qiwen, additional, Gao, Emei, additional, Dong, Zhi, additional, Zhao, Jun, additional, An, Tongtong, additional, Wu, Meina, additional, Zhuo, Minglei, additional, Wang, Yuyan, additional, Li, Jianjie, additional, Wang, Shuhang, additional, Yang, Xue, additional, Chen, Hanxiao, additional, Jia, Bo, additional, Wang, Jingjing, additional, and Wang, Ziping, additional

Published
2018
Full Text
View/download PDF

25. Women patients with small-cell lung cancer using immunotherapy in a real-world cohort achieved long-term survival.

Author

He Y, Kong L, Ji X, Zhuo M, An T, Jia B, Chi Y, Wang J, Zhao J, Li J, Yang X, Chen H, Zhai X, Tai Y, Ding L, Wang Z, and Wang Y

Abstract

Background: Usage of immune checkpoint inhibitors (ICIs) has prolonged the overall survival (OS) of patients with extensive-stage small-cell lung cancer (ES-SCLC). In clinical trials, males accounted for a large proportion, leading to the uncertainty of its efficacy in female patients. We therefore conducted this study to explore the efficacy and safety of using ICIs in female patients with ES-SCLC., Methods: We retrospectively enrolled female SCLC patients and subdivided them into two groups. Group A (n = 40) was defined as ES-SCLC patients who received first-line standard chemotherapy with or without ICIs. Group B (n = 47) included relapsed SCLC patients who were administered with second-line therapies. Kaplan-Meier methodology was used to calculate survival analysis. Chi-squared tests were used to analyze the incidence of adverse events (AEs)., Results: Median progression-free survival (PFS) and median OS favored the ICI-contained cohorts (Group A PFS: 8.3 vs. 6.1 months; OS: not reached vs. 11.3 months; Group B PFS: 15.1 vs. 3.3 months; OS: 35.3 vs. 8.3 months), especially in those patients who received second-line immunotherapies. Patients who received immunotherapy had a slightly higher incidence rate of grade ≥3 AEs (Group A: 71.4% vs. 46.2%; Group B: 44.5% vs. 13.2%). Those who developed grade ≥3 AEs in first-line ICIs cohort had a more favorable survival (PFS: 8.3 vs. 3.2 months; OS: not reached vs. 5.1 months)., Conclusions: Our study suggested that female ES-SCLC patients treated with immunotherapy tended to achieve a relatively longer survival. The incidence of AEs (grade ≥3) was higher in women patients receiving ICIs, which requires monitoring more closely., (© 2024 The Author(s). Thoracic Cancer published by John Wiley & Sons Australia, Ltd.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results